**Supplemental Table 1. Top 10 Antibiotic Agents by Expenditures by Year and Overall, 2010-2015.** (expenditures are presented in millions)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Antibiotic | 2010$\* (%) | 2011$\* (%) | 2012$\* (%) | 2013$\* (%) | 2014 $\* (%) | 2015$\* (%) | Total Expenditures$\* (%) | P value\*\* |
| **Overall** |  |  |  |  |  |  |  |  |
| Doxycycline | 0.82 (7.8) | 0.80(8.1) | 0.86(10.2) | 1.9 (20.8) | 1.4 (15.7) | 1.2 (13.1) |

|  |
| --- |
| 7.0 (12.5) |
|

 | 0.1733 |
| Daptomycin | 0.50(4.7) | 0.59(6.0) | 0.61(7.2) | 0.63(6.9) | 1.3 (14.2) | 1.3 (14.7) |

|  |
| --- |
| 4.9 (8.8) |
|

 | 0.0111 |
| Linezolid | 0.69(6.6) | 0.73(7.5) | 0.71(8.5) | 0.73(8.0) | 0.74 (8.1) | 0.76 (8.6) |

|  |
| --- |
| 4.4 (7.8) |
|

 | 0.0483 |
| Minocycline | 0.80(7.6) | 0.90(9.2) | 0.67 (8.0) | 0.53(5.8) | 0.42(4.6) | 0.32 (3.7) |

|  |
| --- |
| 3.6 (6.5) |
|

 | 0.0171 |
| Piperacillin/ tazobactam | 0.75 (7.1) | 0.53(5.4) | 0.46(5.4) | 0.44(4.8) | 0.46 (5.1) | 0.51 (5.8) |

|  |
| --- |
| 3.2 (5.6) |

 | 0.2799 |
| Levofloxacin | 1.7 (15.9) | 0.97(10.0) | 0.12(1.4) | 0.12(1.4) | 0.10(1.2) | 0.09 (1.0) |

|  |
| --- |
| 3.1 (5.5) |
|

 | 0.0310 |
| Vancomycin | 0.49(4.6) | 0.52(5.3) | 0.52(6.2) | 0.39(4.2) | 0.33(3.6) | 0.38 (4.4) |

|  |
| --- |
| 2.6 (4.7) |
|

 | 0.3420 |
| Azithromycin | 0.53(5.0) | 0.49(5.0) | 0.39(4.6) | 0.35 (3.8) | 0.36 (3.9) | 0.36 (4.1) |

|  |
| --- |
| 2.5 (4.4) |
|

 | 0.0318 |
| Amoxicillin/ clavulanic acid | 0.49(4.6) | 0.45 (4.6) | 0.36(4.3) | 0.34(3.7) | 0.47 (5.2) | 0.29 (3.3) |

|  |
| --- |
| 2.4 (4.3) |

 | 0.4153 |
| Tobramycin | 0.28(2.7) | 0.31(3.1) | 0.35 (4.1) | 0.41 (4.5) | 0.35 (3.9) | 0.29 (3.2) |

|  |
| --- |
| 2.0 (3.5) |
|

 | 0.4174 |

\*Results are reported in $1,000,000s

\*\*P value is evaluating the trend in the proportion of expenditures over five years